The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line setting

The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line setting

BackgroundCyclin-dependent kinase 4/6 (CDK4/6) inhibitors have demonstrated a survival benefit in the second-line treatment of patients with hormone receptor-positive human epidermal growth factor receptor 2-negative advanced breast cancer. However, identifying prognostic biomarkers remains a challe...

Full description

Saved in:

Bibliographic Details
Main Authors:	Marcin Kubeczko, Anna Polakiewicz-Gilowska, Andrea D’Amico, Olgierd Chrabański, Katarzyna Świderska, Ewa Chmielik, Sławomir Blamek, Daria Handkiewicz-Junak, Michał Jarząb
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Series:	Frontiers in Oncology
Subjects:	advanced breast cancer 18Ffluorodeoxyglucose positron emission tomography palbociclib ribociclib abemaciclib
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1454844/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in the adjuvant treatment of patients with high-risk invasive HR+/HER2-early breast cancer: A comprehensive updated meta-analysis of randomized clinical trials
by: Merve Keskinkilic, et al.
Published: (2024-12-01)

Palbociclib-induced Toxic Epidermal Necrolysis: A Case Report with Review of All Cases Secondary to Cyclin-dependent Kinase 4/6 Inhibitors
by: Aurore Devoldere, et al.
Published: (2025-01-01)

Palinopsia associated with the CDK4/6 inhibitor ribociclib during the first-line treatment of metastatic breast cancer: two case reports
by: Tamara Martos, et al.
Published: (2024-12-01)

Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated in routine Bulgarian clinical practice
by: Manoela Manova, et al.
Published: (2023-03-01)

Palbociclib as an Antitumor Drug: A License to Kill
by: Agnieszka Łupicka-Słowik, et al.
Published: (2024-11-01)

Effects of baicalein and fangchinoline on abemaciclib metabolism in vivo and in vitro and molecular docking analysis
by: Xiaohai Chen, et al.
Published: (2025-01-01)

The PRC2.1 subcomplex opposes G1 progression through regulation of CCND1 and CCND2
by: Adam D Longhurst, et al.
Published: (2025-02-01)

The deleterious effects of CDK4/6 inhibition on renal recovery post-acute kidney injury
by: Shanshan Zhou, et al.
Published: (2024-11-01)

Ribociclib-induced vitiligo in a case of metastatic carcinoma of the breast
by: Abhira Deb, et al.
Published: (2025-01-01)

CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells
by: Graziana Digiacomo, et al.
Published: (2022-07-01)

Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells
by: Graziana Digiacomo, et al.
Published: (2024-12-01)

ACSL4 promotes the formation of the proliferative subtype in hepatoblastoma
by: Wei Dang, et al.
Published: (2025-02-01)

Population Pharmacokinetic and Pharmacodynamic Study of Palbociclib in Children and Young Adults with Recurrent, Progressive, or Refractory Brain Tumors
by: John C. Panetta, et al.
Published: (2024-11-01)

Abemaciclib and Letrozole in Metastatic Male Breast Cancer
by: Leon Schönfeld, et al.
Published: (2024-11-01)

LncRNA-ANRIL regulates CDKN2A to promote malignant proliferation of Kasumi-1 cells
by: Jianxia Xu, et al.
Published: (2025-01-01)

18F-FDG PET/CT in the diagnosis and prognosis evaluation of follicular lymphoma
by: LI Zhuohan, HUANG Xinyun, GUO Rui, LI Biao
Published: (2024-08-01)

Potential of non-FDG PET radiotracers for paediatric patients with solid tumours
by: Leonor Teles, et al.
Published: (2024-12-01)

An Analysis of Age-Related Body Composition Changes and Metabolic Patterns in Korean Adults Using FDG-PET/CT Health Screening Data
by: Chang-Myung Oh, et al.
Published: (2025-01-01)

Asymptotic analysis of mathematical model describing a new treatment of breast cancer using AZD9496 and palbociclib
by: Ophir Nave, et al.
Published: (2025-01-01)

RERE-AS1 enhances the effect of CDK4/6 inhibitor Ribociclib and suppresses malignant phenotype in breast cancer via MEK/ERK pathway
by: Zhidong Huang, et al.
Published: (2024-11-01)

Loss of Cdkn1a protects against MASLD alone or with alcohol intake by preserving lipid homeostasis
by: Arantza Lamas-Paz, et al.
Published: (2025-01-01)

Quantitative 18F-FDG PET-CT can assess presence and extent of interstitial lung disease in early severe diffuse cutaneous systemic sclerosis
by: Bo Broens, et al.
Published: (2024-12-01)

[18F]FDG PET-Based Radiomics and Machine Learning for the Assessment of Gliomas and Glioblastomas: A Systematic Review
by: Francesco Dondi, et al.
Published: (2025-01-01)

Safety of Abemaciclib in Indian Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced and/or Metastatic Breast Cancer: A Multicenter, Nonrandomized, Open-Label, Single-Arm, Phase 4 Study
by: Dinesh Chandra Doval, et al.

FDG-PET-based brain network analysis: a brief review of metabolic connectivity
by: Pham Minh Tuan, et al.
Published: (2025-01-01)

The value of 18F⁃FDG PET in the diagnosis and differential diagnosis of Parkinson's disease and multiple system atrophy with parkinsonism⁃predominant
by: DU Xiao‐xiao, et al.
Published: (2024-12-01)

Lichenoid dermatitis induced by abemaciclib in a patient with HR+/HER2- breast cancer
by: Edoardo Mortato, et al.
Published: (2024-11-01)

Sternotomy and extracorporal circulation for fulminant Budd-Chiari syndrome due to leiomyosarcoma of the inferior vena cava
by: Maciej Wiewiora, et al.
Published: (2024-11-01)

An ARFID case report assessment with 18F-FDG PET/MRI and treatment with olanzapine, escitalopram and fluoxetine in adult
by: Meichen Liu, et al.
Published: (2025-01-01)

[18F]FDG PET/CT performs better than CT in determining the bone biopsy site : randomized controlled clinical trial
by: Yujie Chang, et al.
Published: (2024-11-01)

Calculations of Cross-Sections for Positron Scattering on Benzene
by: Małgorzata Franz, et al.
Published: (2024-12-01)

Optimized FDG-PET/MRI protocol reveals metabolic predictors of long-term survival in pancreatic cancer patients
by: Freimut D. Juengling, et al.
Published: (2024-11-01)

Pre-treatment [18F]FDG PET/CT for assessing bone marrow involvement and prognosis in patients with newly diagnosed peripheral T-cell lymphoma
by: Jing Chen, et al.
Published: (2024-12-01)

The Appearances of Brain Metastases of Small Cell Lung Cancer on 18F-FDG PET/CT
by: Hasan Önner, et al.
Published: (2022-08-01)

Capecitabine-induced Hand-foot Syndrome with Hyperpigmentation on Oral Mucosa and Nails: A Rare Entity
by: Suprit Malali, et al.
Published: (2025-02-01)

Research on the characteristics of 18F-FDG PET/CT in mantle cell lymphoma and the discrimination between cellular morphological variants
by: REN Yixuan, et al.
Published: (2024-12-01)

Comparative analysis of arterial involvement in predominant cranial and isolated extracranial phenotypes of giant cell arteritis using 18F-FDG PET-CT
by: Javier Narvaez, et al.
Published: (2024-12-01)

Scientific explanation of e+ and Weyl fermion for injecting semiconductor devices
by: Arwa Saud Abbas
Published: (2025-01-01)

Calculating the size of positronium
by: I.P. Popov
Published: (2024-12-01)

Changes of electron density and defects distribution in binary and ternary iron alloys studied by positron annihilation
by: Udovsky A., et al.
Published: (2017-01-01)